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β-Estradiol hormone replacement therapy (HRT) is used by perimenopausal and postmenopausal 
women to alleviate menopausal symptoms. HRT can upregulate cell proliferation in estrogen 
responsive tissues. We focused on using over-the-counter (OTC) phytoestrogen supplements that 
are high in genistein as an alternative to HRT. Using ovarian cancer cells OVCAR-3, we 
exposed the cells to various OTC phytoestrogen supplements, and performed cell proliferation 
assays to measure the response. We found OTC phytoestrogens had an antiproliferative effect on 
the OVCAR-3 cells, but there is no correlation between the amount of genistein and the strength 
of the antiproliferative effect of the phytoestrogen. In conclusion, we propose taking 
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Ovarian cancer is one of the most commonly occurring cancers in women, affecting 
approximately one in every sixty women, most of whom are over the age of 60 (Khon 2015). 
This cancer can manifest with a number of uncomfortable symptoms, mainly gastrointestinal or 
abdominal in nature (Furuya 2012). Often by the time the patient is symptomatic, the cancer is 
already in the late stages, which are more challenging to treat. Ovarian cancer originates from 
mutations in various ovarian cell types, and can vary in both the rate of proliferation and rate at 
which it metastasizes (Goff et al. 2007). For the purpose of this MQP, we focused on ovarian 
cancer of the epithelial cells in the ovary.  
The most common type of ovarian cancer, epithelial ovarian cancer accounts for nearly 90% of 
all diagnosed cases. It is a particularly aggressive form of ovarian cancer, causing the highest 
number of gynecologic cancer related deaths in the United States at approximately 14,000 deaths 
per year. While this form of cancer can be caused by a mutation in the epithelial cells, 
researchers also noted that estrogen has proliferative effects on the cells (Kang et al. 2001). 
Women most commonly diagnosed with epithelial ovarian cancer tend to be either 
perimenopausal or postmenopausal, with more than 80% of cases occurring in women over the 
age of 40. Many of these women would be experiencing symptoms of menopause, which may be 
relieved by taking estrogen in a treatment known as hormone replacement therapy. When women 
go through menopause, their bodies experience a significant drop in estrogens levels, which 
causes many uncomfortable symptoms that may be alleviated through the addition of 
supplemental estrogen treatments. However, studies have shown an increased risk of ovarian 
cancer in postmenopausal women undergoing estrogen replacement therapy (Rodriguez et al. 
2001). A potential solution to relieving menopausal symptoms without increasing the likelihood 




Estrogen is a naturally occurring steroidal hormone that is synthesized from androgen, a 
hormone responsible for sexual development. Estrogen plays a key role in the development and 
regulation of many structural aspects of the female anatomy, including primary and secondary 
sex characteristics, skin, fat deposits, and bone formation (Li et al. 2014). In order to for estrogen 
to act on a cell, it binds with an estrogen receptor, which is located either intracellularly or on the 
membrane (Li et al. 2014). Because it is a steroid, estrogen is able to diffuse across the cell 
membrane to reach intracellular estrogen receptors as well as the membrane receptors. Once 
estrogen binds to the receptor, the receptor undergoes a conformational change allowing the 
complex to enter the nuclear membrane and bind to a specific DNA locus, the estrogen response 
element, activating gene transcription (Kang et al. 2001). For our purposes, we are studying the 
response of ​estrogen receptor β (ERβ).  
Many varieties of estrogen exists naturally in the body, however 17β-estradiol is the most 
prominent estrogen in terms of usage and binding affinity to receptors. This hormone is 
responsible for the regulation of female sex organs, namely the ovaries. In relation to ovarian 
cancer, it’s been shown that 17β-estradiol exerts antiapoptotic effects on ovarian cancer cells (Ho 
2003).  
Menopause 
In menopausal women, the circulating estradiol level in the bloodstream decreases significantly 
due to the depletion of oocytes in the ovaries (Ho 2003). However, the decrease of estradiol is 
not linear; systemic estradiol levels fluctuate dramatically throughout menopause, especially in 
premenopausal women when levels tend to spike. Thus, hormone replacement therapy (HRT) is 
not typically started until later in the menopausal process, most notably in postmenopausal 
women. While HRT is used to alleviate symptoms of menopause, such as hot flashes, and 
prevent long term effects like osteoporosis and vaginal atrophy, it also increases the risk of 
developing breast or ovarian cancer (Ho 2003). Phytoestrogens are a potentially feasible 
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alternative to HRT as they can also help alleviate symptoms of menopause and are found 
naturally in various plant types and are available OTC in tablets or capsules. 
Phytoestrogen 
Phytoestrogens are plant-based compounds that have estrogenic properties. These compounds 
have most notably been extracted from soy, but also from other plants such as red clover and 
black cohosh root. Phytoestrogens are able to interact directly with human estrogen receptors, 
which has led to the creation of an industry based on dietary phytoestrogen (Hwang et al. 2013a). 
One type of phytoestrogen, genistein, is widely found in OTC phytoestrogen supplements as it is 
the primary type naturally produced in soybeans. 
Genistein has been shown to have antiproliferative effects on estrogen receptor-positive cancers, 
such as certain ovarian cancers (Hwang et al. 2013a). In a study by Kim et. al. in 2014, the 
chemotherapeutics effects of genistein on various cancers in animal models was studied (Kim et 
al. 2014). The researchers concluded that genistein acted as an estrogen antagonist at certain 
dosages against prostate cancer, and that this phytoestrogen may have agonistic effects 
depending on the type of cancer being affected. Another study performed by Hwang et. al. 
specifically tested the effects of genistein on BG-1 ovarian carcinoma cells, specifically because 
the cells were know to proliferate in the presence of 17β-estradiol (Hwang et al. 2013b). In this 
study, the researchers determined that by triggering apoptotic signaling cascades, genistein had 
effective antiproliferative effects on the cancer cells. Many of the phytoestrogen supplements 
used in this study contain genistein, suggesting that there is the potential for suppression of cell 
growth in the ovarian cancer cell line.  
Previous Major Qualifying Projects (MQPs) 
Previous MQP projects focused on the effects of OTC phytoestrogen products on breast cancer 
cell proliferation, but we refocused the phytoestrogen project to examine the effects genistein in 
OTC phytoestrogen products on the proliferation of ovarian cancer cells. Of the OTC 
phytoestrogen products previously chosen to be studied, only Promensil has consistently shown 
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evidence of anti-proliferative effects on breast cancer cells (Gergel et al. 2010). The primary 
chemical compounds found in Promensil are biochanin A and formononetin, which may be 
metabolized to genistein and daidzein respectively. These compounds have been the focus of a 
number of previous MQP studies, but only biochanin A has been shown to have significant 
effects on the breast cancer cells (Gergel et al. 2010). One such study showed that with higher 
concentrations of biochanin A (>10μM), cell proliferation is inhibited, but may be promoted at 
lower concentrations (<10μM) (Gergel et al. 2010). Given the particularly promising data 
acquired from previous MQPs, genistein was chosen for further investigation.  
Ovarian Cancer Cell Line 
Based on our research on estrogen and estrogen receptors in relation to phytoestrogens, we 
studied the effects of phytoestrogen on the ovarian cancer cell line OVCAR-3. This cell line 
derives from an adenocarcinoma on the epithelial tissue on the ovary of a 60-year-old female. 
OVCAR-3 is an adherent cell line that has estrogen and androgen receptors, making it ideal for 
evaluating hormone treatments (Hamilton et al. 1983). Containing high amounts of both ​ERα and 
ERβ, OVCAR-3 is especially sensitive to fluctuations in estrogen levels, specifically 
17β-estradiol, which has been shown to stimulate growth relative to the dose of 17β-estradiol 






OVCAR-3 cells were obtained from Sigma-Aldrich Corp. The cells were cultured in DMEM 
(with 4.5 g/L glucose and sodium pyruvate without L-glutamine, obtained from Corning Cellgro) 
supplemented with 20% Fetal Bovine Serum (FBS) obtained from Equinox, 10 µg/mL bovine 
pancreatic insulin, and 1% Penicillin Streptomycin (Pen/Strep) and incubated at 37°C and 5% 
CO​2​. These cells were split every 2 to 4 days at no more than 1:2 or 1:3 following a 5 minute to 8 
minute trypsinization. 
Reflux 
Extractions were performed on each of the OTC phytoestrogen products. Supplements were 
ground with a mortar and pestle, and each supplement was added to a 250 mL round bottom 
flask with 80 mL of methanol as the solvent. The sample was then refluxed using a water bath at 
68°C for one hour. The refluxed samples were then filtered using Grade 3 Whatman filter paper 
with a 6µm pore size and stored at -20°C.  
Phytoestrogens 
The main active ingredient is listed on each of the phytoestrogen products, which would either be 
the plant name or the specific isoflavone that was sampled. As these products are not regulated 
by the Food and Drug Administration, most of the products did not clearly list the isoflavones 
utilized and in what amounts. As such, we decided to reflux the phytoestrogens based on the 






A one month supply of double strength Promensil was obtained from the company Real Health 
Laboratories. Two tablets, obtained from from lot #16156B, containing 160 mg of isoflavones 
combined were crushed using a mortar and pestle prior to being added to the round bottom flask. 
This was double the recommended daily dose of one tablet per day, due to the size of the tablet 
and the expectation. 
Black Cohosh (Estroven) 
One caplet, obtained from Novasoy Product # 16218EKM15, containing 56 mg of isoflavones 
was emptied directly into the round bottom flask and allowed to dissolve. This was the 
recommended daily dose. 
Black Cohosh (Nature’s Way) 
Three capsules, obtained from Batch # 20006136, containing 540 mg of Black Cohosh root each 
were emptied directly into the round bottom flask. The recommended dosage was one capsule 
three times daily. 
Soy Isoflavones (PipingRock) 
Three capsules, obtained from Product # 08277, containing 13 mg of isoflavones each were 
emptied directly into the flat bottom flask. The serving size was one capsule, and it was 
recommended to take one capsule three times daily.  
Red Clover Liquid Extract (Herb Pharm) 
One hundred and sixty drops of extract containing 2,660 mg of Red Clover leaf and flower was 





Red Clover Capsules (Wild Harvest) 
Three capsules, obtained from Lot # 104214RCL, containing a total 1050 mg of organic Red 
Clover was emptied directly into the round bottom flask. This was the recommended daily 
dosage.  
Yellow Soybeans / Black Soybeans  
Approximately ¼ cup of dry soybeans for both types was first crushed using a mortar and pestle. 
Then the crushed soybeans were added to the round bottom flask with the methanol. This total 
amount was used as it was the serving size listed on the packages the soybeans were sold in. 
High Performance Liquid Chromatography (HPLC) 
Following the initial filtering, 2 mL of each sample was further filtered using a 0.2 µm filter. 
Each HPLC run sampled either 20 µL or 100 µL of a given extract, depending on the purity of 
the sample, using an Agilent 1100 series HPLC system on column two (serial code SB-C18) at a 
flow rate of 1mL/min. The column was washed prior to running the extract using a 100% 
acetonitrile solution. The mobile phase, used to separate and quantify various components of the 
extracts, was a 10 mM ammonium acetate solution with 0.1% trifluoroacetic acid (TFA). The 
ammonium acetate (0.1% TFA) solution was eluted at 100% for 2 minutes, then decreased to 
50% at a gradient from 2 to 24 minutes (Setchell et al. 2001). It was then run with 50% 
ammonium acetate (0.1% TFA) solution and 50% acetonitrile for 5 more minutes before 
returning to 100% ammonium acetate (0.1% TFA) solution (Setchell et al. 2001). 
MTT Assay 
The cells were plated in a CellTiter 96 well flat bottom plate at a density of 10,000 cells per well 
using 100 μL DMEM with 20% FBS, 10µg/mL insulin, and 1% Pen/Strep. After incubating for 
24 hours to allow the cells to adhere to the plate, the media was removed and replaced with 
100μL Phenol Red Free DMEM (PHRED, with 4.5g/L glucose and sodium pyruvate without 
L-glutamine, obtained from HyClone) with 20% FBS, 10µg/mL insulin, and 1% Pen/Strep. The 
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cells were given an additional 24 hours to equilibrate in PHRED. 
Three ten-fold serial dilutions were made for a total of four concentrations (stock, 1:10 dilution 
(D1), 1:100 dilution (D2), and 1:1000 dilution (D3)) of each of the phytoestrogen extracts; 
Promensil, Estroven, Nature’s Way, Women’s Moon Cycle Tea, PipingRock, Herb Pharm, Wild 
Harvest, and both yellow and black soybeans. Dilutions were made in the same manner for 1mM 
β-estradiol dissolved in methanol and 15mM genistein dissolved in methanol. Following the 
secondary 24 hour incubation period, the PHRED was aspirated and replaced with new PHRED, 
at which point 1 μL of each sample (stock extracts and dilutions) were applied to the wells as 
depicted in Table 1. As it is the solvent for the samples, methanol was chosen as a control, as 
well as a media only control chosen to show baseline cell growth. The 1mM β-estradiol and the 
three ten-fold dilutions were used as a positive control. The cells were given 24 hours to incubate 
with the samples in the media. 
 
 
Table 1. Standard Plating Layout​. 96 well plate set-up for the MTT Assay with OVCAR-3 cells. 
Cell-only and methanol were used as a negative control. The 1mM β-estradiol was used as the 
positive control. Each well contained 100 μL of PHRED and approximately 10,000 cells. 
 
Time trials were performed in order to get more accurate results in terms of the doubling time of 
the OVCAR-3 cells. Several 24 hours trials were performed, as were several 48-hour trials and 
two 72-hour trials. In each case, the media was changed every 24 hours and the phytoestrogen 
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treatments were reapplied as well. To perform the MTT assay, the CellTiter 96​®​ AQueous One 
Solution Cell Proliferation Assay kit (Lot #: 0000220603) was used. 20 μL of the reagent was 
added to each well, and the plate was incubated for an additional 4 hours. Then, a 
spectrophotometric plate reader was used to read the absorbance for each well at 570 nm. The 
absorbances from wells containing no cells were averaged and subtracted from the averages from 
each sample set well reading to normalize the data. The results are expressed as percent 







High Performance Liquid Chromatography (HPLC) 
The procedure was performed as described in the methodology section. We performed HPLC on 
the extract samples of Black Soybeans, Estroven, Promensil, Wild Harvest, and genistein. The 
chromatograms were compared to determine genistein concentrations within each.  
Figure 1 shows the chromatogram of genistein, showing a peak at 22.68 minutes.  
 
Figure 1. Chromatogram of genistein.​ HPLC chromatogram of 2.7 ng of genistein in methanol. 
Time (min.) is shown on the x-axis and absorbance (mAU) is shown on the y-axis. 
 
Figure 2 shows the chromatogram of Wild Harvest, showing a peak at 22.55 minutes. This peak 
has an area of 6428.26 mAU*s and a percent area of 9.73. This means that nearly 10% of 
detectable peak area is from this peak, suggesting that the product may contain nearly 10% 
genistein. It is not an exact measurement, as the peak area of each detected compound depends 
on both the amount present and how well it absorbs at the detecting wavelength. This product 
showed the largest peak of all phytoestrogen products tested (refer to Table 2.) 
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 Figure 2. Chromatogram of Wild Harvest Extract.​ HPLC chromatogram of 20µL of Wild 
Harvest extract in methanol. Time (min.) is shown on the x-axis and absorbance (mAU) is shown 
on the y-axis. 
 
Figure 3 shows the chromatogram of Black Soybean, showing a genistein peak at 22.68 minutes. 
This peak has an area of 747.29 mAU*s and a percent area of 0.55%.  
 
Figure 3. Chromatogram of Black Soybean Extract.​ HPLC chromatogram of 50µL of black 
soybean extract in methanol. Time (min.) is shown on the x-axis and absorbance (mAU) is shown 
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on the y-axis. 
Table 2 shows genistein the relative mass in all of the phytoestrogen products. Genistein is 
shown at the top of the table for reference, and is shown to elute at 22.68 minutes. The genistein 
peaks in all other phytoestrogen products were determined by which peak appeared to be closest 
to that time point, so there is some variation, but all within approximately 30 seconds of one 
another. The mAU*s is the area per second, and the percent area is how much of a given peak 
makes up the total area of all detectable peaks. From this we see that Wild Harvest had the 
largest area under the genistein peak, and while black soybean did not have the smallest area 
under the peak, it was also closest to the elution time of genistein.  
 
Table 2. Table of phytoestrogen products and amount of genistein. ​The phytoestrogen products 





The MTT assays were performed following the methods as described in the MTT assay methods 
section. The data were recorded every 24 hours over 72 hours. This time course experiment was 
run twice. Absorbance values are expressed as a percent of the negative control (cells in 1% 
methanol in PHRED). In Figures 4 - 6, the positive control, estrogen, is shown in blue. The three 
phytoestrogens shown in the figures are genistein, Wild Harvest, and black soybean, shown in 
red, green, and purple, respectively. The 4 dilutions tested are shown along the x-axis, the stock 
concentration is unknown and varies for each of the phytoestrogen products. The details of stock 
preparation can be found in Methods.  Raw data from the MTT assays is shown in Appendix A. 
Figure 4 shows the absorbance values expressed as percentage of the negative control. The 
24-hour assay was run three times for genistein, Wild Harvest, and black soybean. There is only 
one data point for estrogen as we needed to change the concentration of the estrogen (from 
10mM to 1mM). The data show cell proliferation of less than 70% in cells treated with either 
Wild Harvest or black soybeans. ​It should also be noted that the dilution series does not appear to 
show dose responsive trends for any of the products the cells were exposed to.  
 
Figure 4. 24-Hour MTT Assay.​ Percent of negative control shown on the y-axis. On the x-axis, 
estrogen stock was at a concentration of 1 mM and the stock genistein was at a concentration of 
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5 mM. D1 is a 10-fold dilution, D2 is a 100-fold dilution, and D3 is a 1000-fold dilution. with 
10-fold serial dilutions shown on the x-axis. 
 
Figure 5 shows the absorbance values expressed as percentage of the negative control. The 
48-hour assay was recorded three times for genistein and estrogen, once individually and twice 
as part of a 72-hour time course. Wild Harvest and black soybean were recorded only once as 
part of a 72-hour time course. The data show that nearly all of the cells treated with the 
phytoestrogen products and estrogen have a greater than 100% proliferation rate after 48 hours of 
incubation. We do not generally see any dilution effects for estrogen, genistein, or black 
soybeans, however, some dilution effects are observed for Wild Harvest. Here we see that 
exposure to stock Wild Harvest extract appears have a biphasic curve, showing a difference 
notable antiproliferative effect between the stock and 10-fold dilution, with a slight decrease with 
the 100-fold dilution. There is a notable increase in proliferation at the 1:1000 dilution.  
 
Figure 5. 48-Hour MTT Assay.​ Percent of negative control shown on the y-axis. On the x-axis, 
estrogen stock was at a concentration of 1 mM and the stock genistein was at a concentration of 
5 mM. D1 is a 10-fold dilution, D2 is a 100-fold dilution, and D3 is a 1000-fold dilution. with 




Figure 6 shows the absorbance values expressed as percentage of the negative control. The 
72-hour assay was recorded twice with genistein and estrogen, and once with Wild Harvest and 
black soybean. The data show that the cells treated with the phytoestrogen products have a 
proliferation rate less than 90% after 72 hours, while estrogen has a proliferation rate greater than 
90%. In this experiment, we see some dilution effects for estrogen, genistein, and Wild Harvest. 
The main dilution effect seen from estrogen exposure is seen in an increase at the 10-fold 
dilution compared to the stock or negative control. For genistein, the 5mM, 0.5mM, and 0.05 
concentrations appear to have stronger antiproliferative effects; the 0.005mM exposure to 
genistein does not appear to have an effect on proliferation. Exposure to stock Wild Harvest 
extract appears to have a slight antiproliferative effect, but a notable decrease in proliferation at 
the 10-fold and 100-fold dilutions, with a slight increase at the 1:1000 dilution. 
 
Figure 6. 48-Hour MTT Assay.​ Percent of negative control shown on the y-axis. On the x-axis, 
estrogen stock was at a concentration of 1 mM and the stock genistein was at a concentration of 
5 mM. D1 is a 10-fold dilution, D2 is a 100-fold dilution, and D3 is a 1000-fold dilution. with 
10-fold serial dilutions shown on the x-axis.  
 
In Figure 7, the amount of genistein in a given product based on milli Absorbance Units (mAU) 
per second is compared to the percent proliferation normalized to the negative control. The 
amount of proliferation was measured by an MTT assay after 24 hours of exposure to a 1:100 
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dilution factor of phytoestrogen products. We see an R​2 ​value of 0.135, which indicates little 
correlation between percent genistein and percent proliferation. This is likely because we have 
one outlying data point, and used the 24-hour time point for reference.  
 
Figure 7. mAU per second compared to the percent proliferation.​ Percent proliferation is 
shown of the 24 hour time point at dilution factor 2 (1:100). The x-axis shows the percent 
proliferation normalized to the negative control (cells in PHRED plus 1% methanol). The y-axis 
shows the percent of genistein in various phytoestrogen products, as determined by the HPLC 
chromatograms.  
 
To test our original hypothesis that higher levels of genistein in OTC phytoestrogen products 
would inhibit cellular growth, we compared the effects of Wild Harvest and black soybeans to 
pure genistein and estrogen. However, at the doses and time points we examined, we could not 
correlate increased genistein concentrations in OTC phytoestrogen products with stronger 
anti-proliferative effects, so we are unable to support our hypothesis. The data show that all 
phytoestrogen products tested decreased cell proliferation by >23%. Interestingly, pure genistein 








The data do not support our hypothesis, as there is no correlation between genistein 
concentration in phytoestrogen samples and percent cell proliferation. The phytoestrogen 
products we chose to show in our results, Wild Harvest and black soybeans, were chosen based 
on their relative genistein concentration. As shown in Table 2, Wild Harvest had the highest 
genistein concentration, while black soybean had one of the lowest genistein concentrations. 
Based on those concentrations, we expected to see a lower amount of proliferation in Wild 
Harvest treated cells than seen in black soybean treated cells. While this was true for the 72-hour 
assay, the reverse was true for the 24-hour assay, and generally cells treated with pure genistein 
showed higher proliferation than those treated with either Wild Harvest or black soybean. To 
support our hypothesis, we would have expected the lowest amount of proliferation from treating 
with a relatively high concentration of pure genistein, followed by Wild Harvest, and finally 
black soybean in relation to the negative control. 
 
Proliferation in the cells treated with phytoestrogen samples at the 72-hour mark is lower than 
that of the positive control. We would expect to see the greatest difference in proliferation by the 
72-hour mark as opposed to the 48-hour or 24-hour time points because we found that we needed 
to split the OVCAR-3 cells roughly every three days. This means that by the 72-hour time point, 
the OVCAR-3 cells would have doubled once. Additionally, the media was changed every 24 
hours, so there may be some discrepancy in the data as the treatment dosage was very small (1µL 
per well) and was administered independently. Despite these possible confounding variables, the 
data show that overall, each phytoestrogen product decreased cell proliferation by at least 23%, 
indicating that they may prevent unregulated cell growth.​ ​Noting the results in Figure 6, we see 
that there is a decrease in proliferation at the 10-fold and 100-fold dilutions. In comparison, there 
is little difference between the 1:100 and 1:1000, indicating that by the 1:1000 dilution there was 
too little extract in the dilution to cause an antiproliferative effect. 
We observed that pure genistein has a weaker anti-proliferative effect than the OTC products that 
contain genistein. This could be because the OTC products also contain other phytoestrogen 
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compounds such as daidzein or ​glycitein, which could be the true source of anti-proliferation 
seen in the experiments. It is also possible that another phytoestrogen compound is working in 
conjunction with the genistein to have a stronger anti-proliferative effect. However, the 
phytoestrogens were expected to have a stronger anti-proliferative effect than the positive and 
negative controls. The controls consistently had unexpected results, as the estrogen control was 
lower than the methanol control and the cell only control. Estrogen treated cells should have had 
a higher level of proliferation than both of the negative controls, but it seemed that the methanol 
and estrogen controls displayed the opposite results. Cells treated with methanol generally 
showed higher levels of proliferation than the cell only control, which could be due to some 
contamination of the methanol stock with organic compounds in the methanol that encouraged 
cell growth. Regardless of the problems with the controls, the phytoestrogen treated cells 
displayed overall antiproliferative effects. 
In Figure 7 of our results section, we see that there is an R​2 ​value of 0.103 for correlation 
between percent genistein and percent proliferation. This tells us that there is little correlation 
between the two. We see that there is one specific outlier, which is from Wild Harvest. It is 
curious that this is the data point that skewed the data, as it showed the least proliferation by the 
72-hour time point. If the outlier Wild Harvest at the 24-hour time point was removed from the 
figure showing genistein concentration compared to the percent proliferation, the result shows 
there is zero correlation between the two (see Appendix B). If we had run proliferation assays 
after 72-hours of exposure to each phytoestrogen product, we might have a clearer picture the 
24-hour time point for reference.  
Future projects should investigate other compounds in OTC phytoestrogens that could have an 
effect on proliferation. It would be worthwhile to determine if another compound in OTC 
products is augmenting the efficacy of genistein or if it is responsible for the decrease in 
proliferation itself. As mentioned earlier, it may be interesting to determine if daidzein is a 
stronger compound in terms of antiproliferative effects than genistein, both in its pure state and 
as a component of OTC phytoestrogen supplements. Regardless of what compound future 
project choose to focus on, it would be advantageous to spike the phytoestrogen supplements 
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with pure genistein to confirm that the peaks we used in our HPLC results were in fact genistein 
peaks. Also, isolating a sample from the time of the known genistein peak would give a much 
more specific sample to test during the MTT assays. Instead of applying 1µL of the original 
refluxed phytoestrogen supplement to each well, 1µL of the isolated sample would be added (as 
well as the subsequent dilutions). We believe that any or all of these suggestions would be 
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Experiment 4: 24 Hour Assay 
 
 
Experiment 4 Repeat: 24 Hour Assay 
 
Experiment 5: 48 Hour Assay 
 
Time Course 1: 24 Hour Data 
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Graph of Genistein Concentration vs Proliferation without Wild Harvest 
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